Abstract:This review focuses on uterine mesenchymal tumors that are defined on a molecular level by a single and unique genetic alteration, that is somehow necessary and sufficient to allow tumor growth and progression. Although diverse from a clinical, morphological and immunohistochemical point of view, the different entities we are going to talk about share both a simple genomic profile with a low number of chromosomal alterations observed by CGH Array (few deletions, gains or amplifications...) and a low mutational burden observed by sequencing technics. Some of these entities are already well known and described in the literature when found outside of the uterus and gynecological tract. It remains intriguing that uterine mesenchymal pathology has been lagging behind when compared to its extrauterine counterpart. How can we explain that when it comes to inflammatory myofibroblastic tumors, abundant numbers of articles have been published since the 70's, but it was only in the early 2000s that the first relevant descriptions of this tumor in the uterus emerged? Certainly, the increased accuracy, availability, and use of molecular biology technics and in particular RNA sequencing in the area of uterine pathology can partly explain the reduction of the gap between soft tissue and uterine pathology we currently observe. Other reasons explaining this gap may be the high prevalence of smooth muscle tumors in the uterus and the abounding diversity of their morphological aspects, which may have partly eclipsed the array of differential diagnoses. Last but not least, one can hypothesize that the relative "simplicity" of hysterectomy procedures, referring to their safety and accessibility, has cured most of the lesions and partly clouded our knowledge regarding the biological potential and natural history of these newly described entities. As a consequence of this situation, our reader will often encounter the wording "uncertain malignant potential", as for some of these rare entities, evidence to establish reliable prognostic variables is still insufficient. We hope this review to be a useful tool to guide pathologists through the diversity and complexity of uterine mesenchymal tumors. As a scientific and medical community, sharing this knowledge will help us to collectively raise our vigilance and awareness by expanding the array of our differential diagnoses. We hope this will lead to more cases being accurately diagnosed, and ultimately, to a deeper knowledge regarding the biological potential and clinical evolution of these tumors. From a therapeutical point of view, the consequences of an accurate diagnosis for the patient are already appreciable through the use of targeted therapy. Examples include: ALK inhibitors in inflammatory myofibroblastic tumor, tyrosine-kinase inhibitors in COL1A::PDGFB rearranged sarcomas or mTOR inhibitors in PEComa.

Uterine Tumours with Myogenic Differentiation Harbouring SRF::RELA Fusions.

Recurrent SRF-RELA Fusions Define a Novel Subset of Cellular Myofibroma/Myopericytoma

Abstract 5240: Functional and Therapeutic Significance of ESR1 Gene Fusions in Breast Cancer

[SRF-rearranged cellular perivascular myoid tumor: a clinicopathological analysis of two cases]

Epithelioid Leiomyosarcoma of Broad Ligament Harboring PGR-NR4A3 and UBR5-PGR Gene Fusions: a Unique Case Report.

Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms

Misdiagnosis of synovial sarcoma - cellular myofibroma with SRF-RELA gene fusion: A case report

S100 and CD34 positive spindle cell tumors of the uterine cervix with EGFR mutation: a hitherto unrecognized neoplasm phenotypically and epigenetically overlapping with "NTRK-rearranged spindle cell neoplasms" of the uterus

Uterine Inflammatory Myofibroblastic Tumor Harboring Novel NUDCD3-ROS1 and NRP2-ALK Fusions: Clinicopathologic Features of 4 Cases and Literature Review

Recurrent RET Fusions in Fibrosarcoma‐like Neoplasms in Adult Viscera: Expanding the Clinicopathological and Genetic Spectrum

Case report: High grade serous fallopian tube carcinoma with rare NRG1 gene fusion presenting as widespread peritoneal carcinomatosis

A Novel CASC15-ALK and TFG-ROS1 Fusion Observed in Uterine Inflammatory Myofibroblastic Tumor

NR1D1-rearranged soft tissue tumour: A clinicopathological and molecular analysis of four additional cases

A Novel <i>CASC15-ALK</i> and <i>TFG-ROS1</i> Fusion Observed in Uterine Inflammatory Myofibroblastic Tumor

["Benign metastasizing leiomyoma"? A case report without evidence for unbalanced cytogenetic aberrations]

COL1A1::PDGFB fusion-associated uterine fibrosarcoma: A case report and review of the literature

SMARCB1 (INI1) Deficient Tumours of the Uterine Cervix: Report of Two Cases, Including One Associated With an NTRK Fusion

NTRK -rearranged spindle cell neoplasms: a clinicopathological and molecular study of 13 cases with peculiar characteristics at one of the largest institutions in China

Sarcomas With RAD51B Fusions Are Associated With a Heterogeneous Phenotype

SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma

[Translocation-associated uterine mesenchymal tumors: The new without forgetting the old. An integrated diagnostic approach]